Buys
Open market- Shares
- +41,678
- Avg price
- $0.8613
- Total value
- +$35,897
John P. Hamill - SrVP/CFO/Prin Fin & Acct Ofcr at Aprea Therapeutics, Inc.
Insider Transactions and Holdings
- Entity Type
- Individual
- Role
- SrVP/CFO/Prin Fin & Acct Ofcr
- Issuer Symbol
- APRE on Nasdaq
- All Insider Reports
- All Insider Reports
John P. Hamill - trading volume in the past year for Aprea Therapeutics, Inc.
Sells
Open market- Shares
- Avg price
- Total value
Net
Past year- Shares
- +41,678
- Share %
- 100%
- Total value
- +$35,897
Holdings reported by John P. Hamill for Aprea Therapeutics, Inc.
Form 4 holding
SrVP/CFO/Prin Fin & Acct Ofcr
Aprea Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 43,528
- Estimated value
- $25,681
- Report date
- 12 Mar 2026
- Price
- $0.5900
- Ownership
- Direct
Form 4 holding
SrVP/CFO/Prin Fin & Acct Ofcr
Aprea Therapeutics, Inc.
- Security class
- Pre-Funded Warrant
- Shares / value
- 30,978
- Estimated value
- $24,999
- Report date
- 31 Mar 2026
- Price
- $0.8070
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
SrVP/CFO/Prin Fin & Acct Ofcr
Aprea Therapeutics, Inc.
- Security class
- Stock Options (Right to Buy)
- Shares / value
- 40,380
- Estimated value
- Report date
- 12 Mar 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
SrVP/CFO/Prin Fin & Acct Ofcr
Aprea Therapeutics, Inc.
- Security class
- Common Warrant
- Shares / value
- 30,978
- Estimated value
- Report date
- 31 Mar 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transactions reported by John P. Hamill for Aprea Therapeutics, Inc.
| Sym | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.